Lacnotuzumab

Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2].

Product Specifications

CAS Number

[1831128-32-5]

Product Name Alternative

MCS110

UNSPSC

12352203

Target

C-Fms

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lacnotuzumab.html

Purity

99.9

Solubility

H2O

Smiles

[Lacnotuzumab]

Molecular Weight

(144.8 kDa)

References & Citations

[1]Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jan 1;28 (1) :106-115.|[2]Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369 (3) :428-442.